ZBIO
Zenas BioPharma, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth n/a ·
share flow n/a ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 58 | +3 | 32.34M | $814.38M | +8 | −5 |
| Q1 2026 | 57 | 0 | 27.25M | $547.68M | +9 | −9 |
| Q4 2025 | 56 | +4 | 18.00M | $649.25M | +4 | n/a |
| Q3 2025 | 12 | 0 | 9.51M | $211.12M | +1 | −1 |
| Q2 2025 | 10 | +3 | 7.80M | $75.56M | +3 | n/a |
| Q1 2025 | 4 | -5 | 2.01M | $15.92M | n/a | −5 |
| Q4 2024 | 9 | -1 | 2.55M | $20.73M | +1 | −2 |
| Q3 2024 | 9 | +9 | 2.41M | $40.14M | +9 | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.50M | New | $24.80M | 0.0% | New | 1 | SEC ↗ ×3 |
| 2 | T. Rowe Price ✦ | 486.85K | New | $8.24M | 0.0% | New | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 117.38K | New | $1.99M | 0.0% | New | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 94.32K | New | $1.60M | 0.0% | New | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 75.00K | New | $1.27M | 0.0% | New | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 57.60K | New | $974,592 | 0.0% | New | 1 | SEC ↗ |
| 7 | Soros Fund Management ✦ | 37.50K | New | $634,500 | 0.0% | New | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 24.86K | New | $420,580 | 0.0% | New | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 13.00K | New | $219,960 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $24.80M | 0.0% |
| T. Rowe Price | $8.24M | 0.0% |
| Millennium Management | $1.99M | 0.0% |
| Citadel Advisors | $1.60M | 0.0% |
| Norges Bank | $1.27M | 0.0% |
| Point72 Asset Management | $974,592 | 0.0% |
| Soros Fund Management | $634,500 | 0.0% |
| Geode Capital Management | $420,580 | 0.0% |
| Two Sigma Investments | $219,960 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 138 holders, 55.37M shares, $1.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.